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Abstract: The rapid scientific interest in gut microbiota (GM) has coincided with a global increase in
the prevalence of infectious and non-infectivous liver diseases. GM, which is also called “the new
virtual metabolic organ”, makes axis with a number of extraintestinal organs, such as kidneys,
brain, cardiovascular, and the bone system. The gut-liver axis has attracted greater attention in
recent years. GM communication is bi-directional and involves endocrine and immunological
mechanisms. In this way, gut-dysbiosis and composition of “ancient” microbiota could be linked to
pathogenesis of numerous chronic liver diseases such as chronic hepatitis B (CHB), chronic hepatitis
C (CHC), alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic
steatohepatitis (NASH), development of liver cirrhosis, and hepatocellular carcinoma (HCC). In this
paper, we discuss the current evidence supporting a GM role in the management of different chronic
liver diseases and potential new therapeutic GM targets, like fecal transplantation, antibiotics,
probiotics, prebiotics, and symbiotics. We conclude that population-level shifts in GM could play
a regulatory role in the gut-liver axis and, consequently, etiopathogenesis of chronic liver diseases.
This could have a positive impact on future therapeutic strategies.
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1. Gut Microbiota
The gut microbiota (GM) is a diverse ecosystem that consists of bacteria, protozoa, archaea, fungi,
and viruses, which exist in a specific symbiosis between each other and the human body as well.
Currently, it is well known that GM plays relevant roles in physiological and pathological conditions
of human health, taking part in digestion, vitamin B synthesis, immunomodulation, and promotion
of angiogenesis and nerve function. In addition, it is unavoidable that the GM has an impact on
pathogenesis of gastrointestinal, hepatic, respiratory, cardiovascular, endocrine, and many other
disorders, arising as “a new virtual metabolic organ” [1].
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The GM colonizes human intestinal tract, which accounts for more than 100 trillion bacteria,
and has a complex genome of 150-fold more genes than the human genome [2]. The majority
of gut microorganisms cannot be cultured using standard techniques, so the development of
culture independent molecular methods based on sequencing of the phylogenetic marker—16S/18S
ribosomal RNA offer better insight in the GM structure. The GM is essentially ecomposed of
the five phyla-Firmicutes (79.4%) (Ruminococcus, Clostridium, and Eubacteria), Bacteroidetes (16.9%)
(Porphyromonas, Prevotella), Actinobacteria (2.5%) (Bifidobacterium), Proteobacteria (1%), and Verrumicrobia
(0.1%) [3]. Lactobacilli, Streptococci, and Escherichia coli are found in small numbers in the gut. Different
genetic and environmental factors influence the GM composition. For example, children born
by natural childbirth inherit about 40% of the mother’s intestinal flora, while GM composition is
very different after the caesarean section. During the first two years of life, the diet is the most
prominent factor that determines GM. Later in life, GM composition depends on age, diet, medications,
and the environment.
Studies published in the last decade confirmed that the GM is implicated in the pathogenesis of
various diseases, such as cancer and autism, depression, Clostridium difficile infection, inflammatory
bowel disease, irritably bowel syndrome, colorectal carcinoma, infectious and non-infectious chronic
liver diseases, obesity, diabetes mellitus type 2, atherosclerosis, and chronic kidney diseases [4–9].
In the present review, the important role of GM in the pathogenesis of most common liver diseases
was discussed.
2. Gut-Liver Axis
GM as a “virtual metabolic organ” makes axis with a number of extraintestinal organs, such as
kidneys, brain, cardiovascular, and the bone system, but the gut-liver axis attracts increased attention in
recent years [10]. The gut-liver axis is a consequence of a close anatomical and functional, bidirectional
interaction of the gastrointestinal tract and liver, primarily through a portal circulation. The symbiotic
relationship between the GM and the liver is regulated and stabilized by a complex network of
interactions, that encompass metabolic, immune, and neuroendocrine crosstalk between them [4].
The tight junctions (TJ) within the gut epithelium represent a natural barrier to bacteria and their
metabolic products [11]. Antigens (Ag) (originating either from pathogenic micro-organisms or from
food) that pass through these connections, are recognized by dendritic cells, or activate the adaptive
immune system by modulating the T cell response. Minimal concentrations of pathogen-associated
molecular patterns (PAMPs), such as lipopolysaccharides (LPS), peptidoglycans, and flagelin, activate
the nuclear factor kappa B (NFKβ) through toll-like receptors (TLRs) and nod-like receptors (NLRs),
which leads to the production of inflammatory cytokines and chemokines that enter portal circulation.
In addition to hepatocyte damage, PAMPs can activate stellate cells involved in fibrosis promotion
and progression, while Kupffer cells are even more responsive to LPS than hepatocytes [12]. Since the
gut-liver axis affects the pathogenesis of liver diseases, it is an important focus of current clinical
research (Scheme 1).
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Scheme 1. Gut-liver axis pathogenesis. Abbreviations: GI, gastrointestinal, LPS, Lipopolysaccharides,
NFKβ, nuclear factor kappa B, NLR, Nod-like receptors, PAMPs, Pathogen-associated molecular
patterns, TJ, Tight junctions, TLR, Toll-like receptors.
3. Disbyosis and Liver Diseases
The gut-liver axis has an impact on pathogenesis of numerous chronic liver diseases such as
chronic hepatitis B (CHB), chronic hepatitis C (CHC), alcoholic liver disease (ALD), non-alcoholic
fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), development of liver cirrhosis,
and hepatocellular carcinoma (HCC) (Table 1).
Table 1. Gut microbiota-associated liver diseases.
Disease Dysbiotic Features References
CHB
Decreased ratio of Bifidobacteriacae/Enterobacteriaceae:
-low levels of Bifidobacteria and Lactobacillus
-high levels of Enterococcus and Enterobacteriaceae
[13]
HBV related cirrhosis Decreased BacteroidetesIncreased Proteobacteria [14]
CHC Decreased BifidobacteriumIncreased Prevotella and Faecalibacterium [15]
HCC Decreased Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp.Increased Escherichia coli
[16]
[17]
HE Production of ammonia and endotoxins by urease-producing bacteria,such as Klebsiella and Proteus [18]
ALD Decreased levels of butyrate-producing Clostridiales speciesIncreased levels of pro-inflammatory Enterobacteriaceae [19]
NAFLD/NASH Increased Firmicutes/Bacteroidetes ratio [20,21]
Cirrhosis Decreased Bacteroidetes and FirmicutesIncreased Streptococcus spp. and Veillonella spp.
[22]
[16]
Abbreviations: ALD, alcoholic liver disease, CHB, chronic hepatitis B, CHC, chronic hepatitis C, HBV, hepatitis B
virus, HCC, hepatocellular carcinoma, HE, hepatic encephalopathy, NAFLD, non-alcoholic fatty liver disease,
and NASH, non-alcoholic steatohepatitis.
In general, an increased intestinal permeability and bacterial translocation could enable microbial
metabolites to reach the liver, which would impair the bile acid (BA) metabolism and promote gut
dysmotility and systemic inflammation. All these conditions could induce gut dysbiosis, which, in turn,
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further increases liver damage. It has been observed that the stage of liver injury correlates closely
with the severity of gut dysbiosis [23]. Alterations in the fecal bacterial flora are described by changes
in the composition of the dominant Bacteroidetes and Firmicutes phyla, including Ruminococcaceae,
Lachnospiraceae, and Clostridiales, which produce short-chain fatty acids (SCFA) that are an energy
source for the intestinal epithelium’s cells, but can also regulate secondary BA metabolism and induce
a regulatory immune process and IgA production.
3.1. Hepatitis B Virus (HBV) Infection
CHB is an important health issue worldwide. Acute HBV infection leads to CHB in just 5% of
adult patients, while the proportion is quite different in children, since more than 90% of exposed
neonates and 30% to 50% of children aged 1 to 5 years fail in HBV clearance. Liver injury is mediated
by HBV induced immune response. TLRs play an important role in the production of interferons
and proinflammatory cytokines and immune cells recruitment in order to suppress viral replication.
It has been established that age-specific seroclearance depends not only on the maturity of the immune
system, but on the GM stability as well [24]. Involvement of GM in HBV clearance was demonstrated
in animal models. Chou et al. showed that adult mice with mature GM managed to clear HBV after
six weeks of infection, which is the opposite among young mice without GM, who remained HBV
positive. The fact that adult mice failed to clear HBV after gut sterilization by antibiotics (6 to 12 weeks),
emphasizes the GM significance in anti-HBV immunity [25]. It also implies new therapeutic strategy
for patients with HBV infection [26]. In fact, the transplantation of fecal microbiota (FMT), in addition
to standard antivirals, has been shown to be effective in HBeAg clearance [27].
Compositional and structural changes of GM have been detected in patients with CHB and liver
cirrhosis. These patients have a decreased ratio of Bifidobacteriaceae/Enterobacteriaceae (B/E), based
on low levels of Bifidobacteria and Lactobacillus, and high levels of Enterococcus and Enterobacteriacea.
In addition, gut permeability is altered when accompanied with bacterial translocation and the
presence of endotoxins in the portal vein, which leads to increased TLS/NLR activation in the
liver with consequential cytokine production and occurrence of liver lesions, progression of fibrosis,
and development of cirrhosis and HCC [2,13]. Wei et al. have demonstrated that GM of patients
with HBV-related cirrhosis contained lower levels of Bacteroidetes (4% vs. 53%) and increased levels
of Proteobacteria (43% vs. 4%) compared to the heathy group [14]. In an other study, patients with
alcohol-related and HBV-related cirrhosis showed decreased GM diversity, compared to healthy
individuals, with a predominance of Enterobacteriaceae and Streptococcaceae [28].
3.2. Hepatitis C Virus (HCV) Infection
CHC is a global health problem that leads to progressive liver fibrosis and the cirrhosis
development in 20% to 30% of untreated patients after 20 to 30 years. It has been estimated that
1% to 4% of these patients develop HCC each year [29]. GM has been rarely analyzed in patients
with HCV infection. According to published data, the GM found in HCV patients shows lower
microbial diversity in comparison to those in healthy controls [15,28,30]. CHC could alter microbiota
composition through IgA produced by HCV infected gastric B-lymphocyte. GM found in Egyptian
patients with CHC contains more Prevotella and Faecalibacterium and less Acinetobacter, Veillonella,
and Phascolarctobacterium than healthy individuals. In the study of Aly et al., Bifidobacterium was
detected only in GM of the healthy group, posing the possible new role of Prevotella/Faecalibacterium
vs. Bifidobacterium ratio as a biomarker for CHC and fibrosis progression [15]. Disease progression
could bring more profound changes in CHC patients’ GM. Therefore, according to Heidrich et al.,
decreased diversity was more pronounced in HCV patients’ with established cirrhosis than in those
with less advanced CHC [31]. Liver cirrhosis per se could be an independent risk factor for dysbiosis
regardless of the HCV viral load. This hypothesis is in agreement with a study performed by Bajaj
et al. who found that patients with HCV cirrhosis have gut dysbiosis regardless of long-term HCV
eradication. A sustained virological response (SVR) did not improve gut dysbiosis in patients with
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HCV cirrhosis, due to refractory systemic inflammation and endotoxemia in these individuals [32].
Bacterial translocation was described in patients with CHC and together with increased intestinal
permeability (“leaky gut”), it poses a well-established milieu with TLR/NLR activation and expression
of pro-inflammatory cytokine genes, especially in those with cirrhosis [33].
3.3. Alcoholic Liver Disease
Alcohol abuse is a prominent cause of liver damage worldwide. GM is recognized as a key
player in the severity of liver injury in ALD, in addition to the quantity of consumed alcohol and
genetic predisposition (patatin like phospholipase domain containing 3 (PNPLA3), Transmembrane
6 superfamily 2 human gene (TM6SF2), membrane bound O-acyltransferase domain containing
7 (MBOAT7), and solute carrier family 38 member 4 (SLC38A4) etc.) [34]. Alcohol consupmtion
leads to small and large intestine overgrowth and modulation of GM composition in both animals
and humans [35]. Alcohol and its degradation products disrupt epithelial TJ leading to increased
intestinal permeability and inflammation [34]. Gut-derived PAMPs (e.g., endotoxin) are increased
after heavy alcohol intake [36]. Ethanol consumption alters the GM composition through SCFAs
modulation. Intestinal levels of SCFAs are lower after alcohol consumption with the exception of
increases in acetic acid levels, which is the metabolite of ethanol [37]. Alcoholic abuse was shown to
be associated with decreased levels of butyrate-producing Clostridiales species order and increased
levels of pro-inflammatory Enterobacteriaceae. In those with established cirrhosis, multiple members
of the Bacteroidales order were depleted with a rise of taxa normally inhabiting the oral cavity [19].
3.4. Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
NAFLD is one of the most important causes of liver disease worldwide, with global prevalence
of 25%. NAFLD is one of the top risk factors for HCC and is predicted to become the most common
indication for liver transplantation [38]. NAFLD is a consequence of triglyceride accumulation in
the hepatocytes and is considered to be the hepatic manifestation of obesity and the metabolic
syndrome [39]. About 20% of patients with NAFLD develop NASH, which is a chronic hepatic
inflammation that can progress to cirrhosis, end stage liver disease (ESLD), and HCC. Pathogenesis
of NASH is not yet fully elucidated, but it is described as a “two hit” phenomenon. The primary
event is lipid accumulation with alterations of lipid homeostasis associated with obesity, insulin
resistance, and adipokine abnormalities. The second “hit” is a combination of oxidative stress, lipid
peroxidation, mitochondrial dysfunction, BA toxicity, cytokine-mediated recruitment, and retention of
inflammatory cells [40]. Obesity is associated with dysbiotic gut microbiota, with decreased diversity
and an increased Firmicutes/Bacteroidetes ratio [20]. A similar Firmicutes/Bacteroidetes ratio was found
in diabetes patients as well. Endogenous ethanol is constantly produced by microbiota, regardless
of oral alcohol intake, especially in those with a sugar-rich diet. Increased ethanol production by
microbiota in obese humans and mice leads to the activation of TLRs in the liver, cytokine production,
and alters the BA profile. Endogenous ethanol serum concentrations are significantly higher in
patients with NASH compared to obese or healthy controls [41]. Gut dysbiosis in patients with
NAFLD/NASH promotes insulin resistance, de novo lipogenesis in liver, and also increases intestinal
permeability, which promotes chronic PAMPs exposure and oxidative stress caused by increased
endogenous ethanol [21]. Endotoxin/TLR4 signalling contributes to the development of fibrosis
and progression to cirrhosis through hepatic stellate cell activation. The GM plays a critical role
in the conservation of the mainstream BA pool, which transforms BA to several metabolites by
oxidation/epimerization, deconjugation, esterification, 7-dehydroxylation, and desulfatation. Changes
in any of these modulations is a cause of disease. GM dysbiosis in NAFLD could affect the conversion
of primary bile acids into secondary bile acids [42]. It has been observed that the bacteria able to
make this transformation are decreased in the NAFLD cirrhosis fecal samples. In particular, there is a
higher level of Enterobacteriaceae (that could be potentially pathogenic) with lower Ruminococcaceae,
Lachnospiraceae, and Blautia (with a 7α-dehydroxylating activity) abundances.
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Currently, the roles of BA and nuclear receptors are also strongly considered. The BA primarly
synthesized in the liver are secreted to the gallbladder and then released into the duodenum following
food ingestion. In the gut, the size and composition of the BA pool can be modified by GM via the
biotransformation of primary into secondary BA. The BA contributes to the emulsification and fat
solubilization but also activates the expression of a nuclear bile acid receptor FXR (farnesoid X receptor)
and a membrane G protein-coupled receptor TGR5. The reduction of the secondary BA synthesis
attributed to GM dysbiosis lowers the activation of nuclear receptors FXR and TGR5 in the ileum, which
leads to retained bile salts, perpetuation of gut permeability, small bowel translocation, and bacterial
overgrowth, which contributes to liver disease [43]. The FXR plays a key role in mediating the crosstalk
between the host and GM, especially through the modulation of enterohepatic BA circulation. FXR
exerts bile-acid regulatory effects via a tissue-specific mechanism. [44]. In detail, in the liver, FXR
induces the expression of the small heterodimer partner (SHP), which inhibits CYP7A1 (Cholesterol
7 alpha-hydroxylase) expression, while, in the intestine, FXR increases the levels of circulating
fibroblast growth factor 19 (FGF19), which decrease the expression of CYP7A1 and cytochrome
P450 12a-hydroxylase B1 (CYP8B1). Therefore, this leads to the inhibition of BA synthesis [45].
FXR activation has been known to reduce triglyceride levels suppressing the synthesis and uptake
of the fatty acids in the liver [46]. In addition, the FXR roles in decreasing inflammation have been
emerging [47]. Lastly, related to glucide metabolism, FXR reduces insulin resistance, gluconeogenesis,
increases glycogenesis, and, therefore, decreases the blood glucose amount. A more fine elucidation of
FXR functions in liver and intestine needs further research. Furthermore, mice models showed that
FXR activation, induced by BA products (converted by GM) might protect against bacterial overgrowth,
gut permeability, and small bowel translocation [48]. The degree of FXR activation could be regulated
by GM dysbiosis, inducing BA alteration and, hence, liver disease secondary to retained bile salts
and a leaky gut. Bacteria, translocated from the gut, may additionally decrease FXR activation within
hepatocytes, which leads to decreased BSEP (bile salt export pum) activity.
The bile acid-activated FXR and TGR5 has a protective role in liver disease progression,
which means the activation of both receptors has been proposed as therapy. Many activators of
FXR and TGR5 have been developed from bile acid analogues, which are able to decrease hepatic
steatosis and inflammation [49]. FXR agonists such as obeticholic acid have already been recognized
as a new therapeutic venue for NASH and cholestatic diseases. NASH patients exhibit increased fecal
primary BAs, primary/secondary BAs fecal ratio, and plasma and hepatic BAs concentrations [50].
This cytotoxicity can lead to NASH progression and finally to liver cirrhosis.
3.5. Hepatic Encephalopathy (HE) and Spontaneous Bacterial Peritonitis (SBP)
In all patients with ESLD, regardless of its etiology, HE and SBP commonly occur. HE is considered
to be a consequence of high ammonia level, but GM and bacteria’s products, such as amino acid
metabolites (indoles, oxindoles) and endotoxins, are also involved in HE development. The connection
between HE and GM is the production of ammonia and endotoxins by urease-producing bacteria,
such as Klebsiella and Proteus, which are present in GM [18]. It has been shown that microbiota of the
sigmoid colon in liver cirrhosis patients differs in those with HE when compared with patients without
HE [51]. Gut dysbiosis in liver cirrhosis also contributes to the development of Spontaneous Bacterial
Peritonitis (SBP) through damaged intestinal barrier and a higher degree of microbial translocation [52].
3.6. Hepatocellular Carcinoma
HCC is the most common primary malignancy in adults with chronic liver disease and liver
cirrhosis [53]. HBV and HCV infection, alcohol abuse, and dietary aflatoxin are major risk factors for
the development of HCC. Although HBV and HCV account for 80% to 90% of overall HCC, regarding
the obesity pandemic, an emergance of potent direct acting antivirals for HCV and worldwide available
vaccine for HBV, it can be expected that HCC epidemiology will change in the future [54]. An alarming
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rise in the incidence of NAFLD and NASH was accompanied by an increased development of
NASH-related HCC incidence [55].
All previously mentioned mechanisms, leaky gut, endotoxemia, TLR, dysbiosis,
and immunomodulation promote the development of HCC [56]. The gastrointestinal tract
contributes to homeostasis by maintaining an intact barrier against LPS and intestinal bacteria. In the
case of increased intestinal permeability, bacterial translocation and LPS accumulation will lead
to intestinal bacterial overgrowth and changes of GM composition. In patients with chronic liver
diseases/cirrhosis, detoxification, degradation, and clearance of LPS and other bacterial products is
compromised [57]. Altered microbiota is generally presented in HCC patients [58]. HCC patients have
been reported to have high levels of Escherichia coli and other gram-negative bacteria in GM, which are
associated to increased LPS serum levels [16]. Oribacterium and Fusobacterium are the most commonly
isolated bacteria from tongue swab of HCC patients. On the other side, GM of HCC patients contains
reduced levels of Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. [17]. Unlike merely
microbial species, it was shown that microbial metabolism, iron transport, and energy-producing
system significantly differ between GM of HCC patients and healthy control [58]. TLR4 expressed by
activated stellate cells react to low LPS concentrations, which ensures the development of fibrosis and
cirrhosis. The significance of GM and TLR4 activation in hepatocarcinogenesis have been studied in an
animal model. It has been demonstrated that GM and TLR4 activation promote HCC development by
increased cell proliferation and suppression of apoptosis [59].
4. Current Perspectives on the Therapeutic Options
Dietary modification is the focus for many studies on GM modification, but results are not
encouraging due to poor compliance [11]. Different treatments options have been developed in the
last decade in the attempt to modify pathogenesis factors involved in GM-liver axis, but results are
still unsatisfactory [60]. Antibiotics, probiotics, prebiotics, and symbiotics are gaining increasing
importance as a treatment option for GM manipulation and its impact on different liver diseases
(Table 2).
Table 2. Therapeutic options for gut-microbiota alteration in liver diseases.
Disease Therapeutic Option References
NAFLD/NASH -“VSL #3“ (Streptococcus thermophilus, Bifidobacterium breve, B. longum, B. infantis, Lactobacillusacidophilus, L. plantarum, L. paracasei, L. bulgaricus) reduces liver injury [61,62]
Cirrhosis -Diet rich in fermented milk, vegetables, cereals, coffee, and tea is associated with a highermicrobial diversity and lower risk for cirrhosis progression [63]
HCC
-Probiotics can contribute to the inhibition of aflatoxin B-induced hepatocarcinogenesis,
restore intestinal dysbiosis, reduce LPS levels and decrease tumor size
-Probiotic fermented milk and chlorophyllin slow down tumor growth and volume for 40%
[58,99]
[64]
HE -Lactobacillus, Bifidobacterium, non-pathogenetic strains of Escherichia coli, Clostridium butyticum,Streptococcus salivarius, Saccharomyces boulardii and VSL#3 improve HE [65–69]
Abbreviations: NAFLD, non-alcoholic fatty liver disease, HCC, hepatocellular carcinoma, HE, hepatic
encephalopathy, and NASH, non-alcoholic steatohepatitis.
4.1. Antibiotics, Probiotics, Prebiotics, and Symbiotics
Positive effects of antibiotics on small-intestinal-bacterial-overgrowth related liver damage was
shown in the recent literature, which confirms the relationship between GM and liver diseases [70].
Probiotics are micro-organisms with a healthy impact to the human, while pre-biotics are food
ingredients, which can not be digested and, on that way, help gut peristaltic and selectively stimulate
growth of intestinal bacteria. Some prebiotic food products, like pectin, have been shown to prevent
liver injury in rodent models by restoring the levels of Bacteroides and appears to be a promising
therapeutic agent [71]. New term “symbiotics” represent combinations of a probiotic and prebiotic.
From this group, the most potential for being used as potential treatment of chronic liver diseases
have probiotics [11,70]. Probiotics have a significant influence on the gut-liver axis, including the
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immunomodulatory and anti-inflammatory role on intestinal microflora and intestinal barrier function,
but also metabolic effects on non-gastrointestinal organs and systems.
Not all probiotic species have the same impact on GM modulation. For example, different
strains of Lactobacillus spp. are associated with divergent obesity consequences, pro-obesity and
anti-obesity [72]. A study on murine diet-induced obesity showed the opposite metabolic outcomes
after different targeted GM manipulation with vancomycin vs. probiotic strain Lactobacillus salivarius,
but microbiota changes were similar. On the other side, a recent human study investigating the effect
of the Lactobacillus salivarius Ls-33 on a series of inflammatory biomarkers in obese adolescents could
not detect any significant impact on the metabolic syndrome [73,74]. These results suggest that no
generalization could be done. Use of probiotics and antimicrobials in chronic liver diseases should
be determined in accordance to specific gut-liver axis pathology. Although there are a number of
findings from animal and human studies, this topic requires more case-control prospective studies
with a significant number of patients.
4.2. Fecal Microbiota Transfer (FMT)
Next to probiotics and prebiotics, fecal microbiota transfer attracts a lot of attention currently
as a possible option for GM editing. FMT is the introduction of a fecal suspension derived from a
healthy donor into the intestinal tract of the patient. Animal studies revealed altered GM composition
after FMT in alcohol-sensitive mice and prevented alcohol-induced liver lesions [71]. Wang et al.
showed potential protective effects of FMT in the improvement of motor activity in a rat model of
HE. In addition, FMT had a superior impact on alteration of the intestinal mucosal barrier function,
in comparison to probiotics [75]. A different study with the rat model of HE found that rectal
administration of a Lactobacillus species suppressed bacterial cell proliferation [76]. Regarding the
clinical trial, a pilot study was performed in eight male patients with severe alcoholic hepatitis (SAH)
and compared outcomes with historical controls. Researchers found that one week of FMT was
effective and safe in SAH patients and improved the values of liver disease severity and survival at
one year [77]. In addition, an open label randomized clinical trial was performed in 20 male patients
with cirrhosis and recurrent HE despite treatment with lactulose and rifaximin, comparing FMT vs.
standard of care [78]. The result showed that FMT from a rationally selected donor (chosen for having
the highest abundance of Lachospiraceae and Ruminococcaceae in a universal stool bank) improved
cognition, reduced hospitalizations, and ameliorated the dysbiosis condition in cirrhosis with recurrent
HE. However, it is not yet known what consequences FMT may excert on dysbiosis in the upper
gastrointestinal tract, which may be more involved in liver disease pathogenesis. Further clinical trials
benefiting FMT for management of chronic liver diseases are ongoing. It is important to highlight
that FMT is a promising therapy to restore a healthy microbiota. However, its safety profile among
vulnerable liver disease patients that are usually immunosuppressed and, so at risk of bacteremia,
due to bacterial translocation, is unknown.
4.3. NAFLD
Several pharmacologic treatments for NAFLD exist, but a standard treatment is not yet
established [79,80]. Recent animal model-studies on NAFLD and HE reported beneficial
therapeutic effects of probiotics [81–83]. In mice models, probiotics had positive effects on
oxidative and inflammatory liver damage mediated by c-Jun N-terminal kinase (JNK) and NF-KB
correlated with TNF-α regulation and insulin resistance. The results showed improvement of
histological findings including reduced fat deposits and liver damage, with decreased serum
alanine aminotransferase (ALT) levels [81,83,84]. Apart from animal studies, several clinical
trials of probiotics administered to patients with NAFLD have been reported. The mixture
of Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis,
Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus bulgaricus
has joint name “VSL #3” and represent the most-studied probiotic [61]. A meta analysis
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of effects of probiotic on NAFLD/NASH showed that probiotic therapies can reduce liver
aminotransferases, total-cholesterol, TNF-α, and improve insulin resistance in NAFLD/NASH
patients [62]. Administration of non-complete VSL #3 (only Lactobacillus bulgaricus and Streptococcus
thermophilus) decreased ALT and aspartate aminotransferase (AST) levels, but had no impact on
cardiometabolic risk factors [85]. Ma et al. found that the probiotic therapy significantly decreased the
levels of ALT, AST, total-cholesterol, high-density lipoprotein (HDL), and TNF-α in the serum, and
the homeostasis model assessment of insulin resistance [62]. Comparing single strains, Bifidobacterium
longum showed more positive effects than Lactobacillus acidophilus in NAFLD treatment and these
beneficial effects correlated to GM modifications [61]. It was demonstrated that GM modulation by
linoleic acid and Bifidobacterium resulted in an increase of conjugated linoleic acid (CLA) and altered
fatty acid composition of liver [86]. Consequently, by producing CLA as a microbial metabolite, VSL #3
correlates with NAFLD’s improvement [86]. In additional studies (of Malaguarnera et al. and Tanock
et al.), probiotics were used with prebiotics in NAFLD patients, and the combination significantly
reduced the AST and ALT levels and liver steatosis [87,88].
Prebiotics also hold promise for the NAFLD management. In animal models, the administration
of prebiotics could lead to reduced liver inflammation in obese mice through a glucagon-like
peptide-2-dependent effect on the gut barrier [89]. There is convincing evidence from short-term high
quality human trials supporting the use of dietary prebiotics as a potential therapeutic intervention
for NAFLD. However, further studies are needed to correlate these findings with changes in GM [90].
Although most of the conducted studies have limitations including small sample sizes and a lack of
data about the patients’ diets and life style, the treatments with probiotics and prebiotics for patients
with NAFLD are promising [91].
Moreover, a recent meta-analysis study demonstrated that, in addition to probiotics and prebiotics,
ω-3 supplementation could have effects on the gut microbiota, which improves NAFLD [92]. It has
been shown that n-3polyunsaturated fatty acids (n-3 PUFAs) decrease Akkermansia, Epsilon proteobacteria,
Bacteroides, and increase Clostridia [93]. Lastly, the n-3 PUFAs administration has been related to an
increment of butyrate-producing bacteria [94].
4.4. Cirrhosis
Qin at el. showed reduced Bacteroidetes and Firmicutes levels and increased Streptococcus spp.
and Veillonella spp. levels in GM by metagenomics analyses in cirrhotic patients, compared to a
healthy population [22]. Streptococcus spp. and Veillonella spp. are bacteria regularly living in oral
cavity, which implicates that an increased number of oral bacteria in GM may be related to cirrhosis
development [16]. It was reported that the gut microbiome plays a role in the CHB progression to severe
liver failure, including inflammation and pathogenic metabolic accumulation [75]. The connection
between GM and cirrhosis was recently confirmed in the study of Bajaj et al., which showed a significant
improvement of diversity and symbiosis of GM after liver transplantation in a patient with severe
cirrhosis [95]. In the recent international cirrhosis cohort study, Bajaj et al. showed that diverse
GM achieved by diet is associated with a lower risk for cirrhosis progression and reduced risk of
hospitalization [63]. Although the functions of these bacteria in the pathogenesis and complications
of liver cirrhosis is not yet clear, these findings give hope for a new therapeutic strategy against liver
cirrhosis by focusing on the GM modulation.
4.5. Hepatic Encephalopathy
Probiotics inhibit the activity of bacterial ureases, modulate intestinal pH values, and reduce
ammonia absorption in HE [96]. Administration of probiotics and prebiotics could improve HE by
altering GM [18]. It is already shown that Lactobacillus, Bifidobacterium, non-pathogenic strains of
Escherichia coli, Clostridium butyricum, Streptococcus salivarius, and Saccharomyces boulardii, and VSL
#3 altered GM composition and improve HE [97]. A number of conducted clinical trials indicate
that probiotics could be helpful in overt HE [65–69]. In a systematic review of McGee et al., it was
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found that patients treated with probiotics appeared to have reduced plasma ammonia concentrations
compared to patients treated with placebo or no intervention. On the other side, treatment without
probiotics and synbiotics did not significantly alter mortality and quality of life [65]. The possible
explanation is that the sample of study groups was small in the reviewed control trials, as well as
quantities of the probiotics were not uniform. Use of probiotics for the secondary HE prophylaxis
was studied by Agrawal et al. Although not statistically significant, the occurrence rate of recurrent
HE was lower in patients who received probiotics or lactulose compared to those without treatment
(34% and 27%, respectively, vs. 57%) [67]. In another prospective study by Lunia et al., it was shown
that probiotics could be effective in preventing overt HE. Patients with liver cirrhosis who had not
experienced overt HE and who received the probiotics were less likely to develop overt HE compared
to controls (1.2% vs. 19%) [67]. Among the various probiotics, the most efficacious species for HE
appeared to be Lactobacilli and Bifidobacteria [97]. The most studied probiotic is the Lactobacillus GG
AT strain 53103 (LGG). Safety and tolerability of administrated therapy is especially important for
the patients with cirrhosis and HE. It is shown that LGG is safe and well tolerated in patients with
cirrhosis and could cause reductions of the endotoxemia and TNF-α production [98]. However, due to
a specific clinical course, randomized controlled trials are needed before probiotics can be routinely
used in patients with HE.
4.6. HCC
The mouse model has shown that the obesity-induced intestinal microbial dysbiosis can
lead to HCC [99]. Reports of the therapeutic prevention of HCC using probiotics are limited to
aflatoxin-induced HCC. Findings of a clinical and animal model studies suggested that probiotics can
contribute to the inhibition of aflatoxin B-induced hepatocarcinogenesis, restore intestinal dysbiosis,
reduce LPS levels, and decrease the tumor size [59,100]. An animal study regarding the potential of
Lactobacillus plantarum, isolated from Chinese traditional fermented foods, in reducing the toxicity
of aflatoxin B1, showed that L. plantarum C88 treatment increased fecal aflatoxin B1 excretion and
regulated defense system’s deficit of antioxidant in the mice model [100]. Lastly, a study with an HCC
rat model showed that probiotic fermented milk and chlorophyllin slow down tumor growth and
volume for 40%, by reducing expressions of c-myc, bcl-2, cyclin D1, and rasp-21. After treatment with
probiotics, mice had high levels of Prevotella and Oscillibacter in their fecal microbiota [64]. Dapito et al.
also found that gut sterilization and TLR4 inactivation reduce HCC by 80% to 90% and could serve as
potential HCC prevention strategies [59].
5. Conclusions
Knowledge regarding the gut-liver axis has improved in the last decade. It is confirmed that
gut microbiota has a strong relationship with liver and plays a significant role in the pathogenesis of
chronic liver diseases, including NAFLD, fibrosis progression, CHB, cirrhosis, HE, HCC, etc. However,
the mechanism of this connection in different liver diseases is still unclear. Our knowledge about the
clinical significance of probiotics’ use in liver disease is starting to take shape. Although clinical and
experimental studies confirmed the therapeutic potential of probiotics in chronic liver diseases, data on
safety assessments, and impact on microbiota-host interactions are missing. Recently, many animal
studies tried to reveal these gaps, but differences in physiology and variations in the molecular targets
between mice and humans can lead to translational limitations. Large prospective controlled studies
with a standardized dose of probiotics therapy and duration, liver biopsy, and patients’ follow-up
appointments are required to confirm these encouraging results.
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